European guidelines on heart failure : pharmacotherapy
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
The new 2021 guidelines of the European Society of Cardiology (ESC) have broken with the old step by step treatment of heart failure and have fundamentally revised the strategy in the pharmacotherapy setting. For patients with heart failure and reduced ejection fraction ≤ 40%, the 4 substance groups angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor-neprilysin inhibitors (ARNI), beta blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose transporter 2 (SGLT2) inhibitors are now recommended as early as possible after diagnosis. Completing the substance groups has priority over increasing the dosage of the individual substances. This makes it necessary to rethink current clinical practice, especially as the guidelines are reluctant to give concrete instructions for implementation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Herz - 48(2023), 2 vom: 14. März, Seite 89-94 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Europäische Leitlinien Herzinsuffizienz: medikamentöse Therapie |
|---|
| Beteiligte Personen: |
Grundmann, Sebastian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.03.2023 Date Revised 20.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00059-022-05157-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352064285 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352064285 | ||
| 003 | DE-627 | ||
| 005 | 20231226052850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00059-022-05157-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM352064285 | ||
| 035 | |a (NLM)36695878 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Grundmann, Sebastian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a European guidelines on heart failure |b pharmacotherapy |
| 246 | 3 | 3 | |a Europäische Leitlinien Herzinsuffizienz: medikamentöse Therapie |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2023 | ||
| 500 | |a Date Revised 20.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a The new 2021 guidelines of the European Society of Cardiology (ESC) have broken with the old step by step treatment of heart failure and have fundamentally revised the strategy in the pharmacotherapy setting. For patients with heart failure and reduced ejection fraction ≤ 40%, the 4 substance groups angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor-neprilysin inhibitors (ARNI), beta blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose transporter 2 (SGLT2) inhibitors are now recommended as early as possible after diagnosis. Completing the substance groups has priority over increasing the dosage of the individual substances. This makes it necessary to rethink current clinical practice, especially as the guidelines are reluctant to give concrete instructions for implementation | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Angiotensin-converting enzyme inhibitors | |
| 650 | 4 | |a Beta blockers | |
| 650 | 4 | |a Ejection fraction | |
| 650 | 4 | |a Mineralocorticoid receptor antagonists | |
| 650 | 4 | |a Sodium-glucose transporter 2 inhibitors | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Mineralocorticoid Receptor Antagonists |2 NLM | |
| 700 | 1 | |a von Zur Mühlen, Constantin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Herz |d 1993 |g 48(2023), 2 vom: 14. März, Seite 89-94 |w (DE-627)NLM000324086 |x 1615-6692 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2023 |g number:2 |g day:14 |g month:03 |g pages:89-94 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00059-022-05157-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2023 |e 2 |b 14 |c 03 |h 89-94 | ||